$ALAB

Gajendra Sanjay sold $39.5M of ALAB (indirect holdings)

Gajendra Sanjay (President and COO) sold 136,709 indirectly-held shares of Astera Labs, Inc. (ALAB) at $289.13 ($39.53M total) on 2026-05-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gajendra Sanjay
Published May 26, 2026, 8:48 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 26, 2026, 8:56 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ALAB
Neutral
medium confidence
Mentioned
$ALAB
Relevance
8/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALABNeutralMed
01

Why it matters

The disclosure reports an open-market sale of 136,709 shares (~$39.53M) executed under a pre-arranged 10b5-1 plan, which generally lowers the probability that the sale signals deteriorating near-term outlook.

02

Market read

Traders may monitor for sentiment impact from large insider selling, but the 10b5-1 designation suggests planned activity rather than a new negative catalyst.

03

What to watch

Market may overreact to the dollar amount; traders should check whether there were concurrent insider buys/sales or other filings around the same period.

Relevance 8/10Timing: Immediate (filed 2026-05-26) but primarily informational; potential short-term headline-driven volatility.

Background

The article is an SEC Form 4 insider transaction disclosure for Astera Labs, Inc. (ALAB) by President and COO Gajendra Sanjay.

Company-level read

Ticker impact

$ALABNeutralMedium confidence
Context

Astera Labs COO sold $39.53M of ALAB shares in an open-market transaction under a pre-arranged 10b5-1 plan dated 2026-05-21.

Expected impact

Low likelihood of sustained price impact; any reaction may be brief and fade as the filing is understood as planned selling.

Evidence & confidence

Form 4 shows a large sale ($39.5M) but explicitly states it was executed under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal sector read-through; this is company-specific insider liquidity disclosure rather than operational/regulatory change.

None indicated; filing is US SEC EDGAR and not tied to regional demand/supply shifts.

None indicated; no international transaction or guidance change mentioned.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect routine diversification/compensation rather than negative fundamentals.

Key entities

  • Astera Labs, Inc.

    Company whose shares were sold by an officer/director under a 10b5-1 plan.

  • Gajendra Sanjay

    President and COO; sold 136,709 ALAB shares for ~$39.53M.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRDOMed

3 Under-the-Radar AI Stocks Wall Street Is Missing

Credo Technology (CRDO) reported Q4 2026 revenue of $437M, up 157% YoY, with guidance for 80% YoY growth in 2027. Astera Labs (ALAB) saw Q2 2026 revenue of $392.4M, up 104% YoY, with Scorpio X series ramping ahead of schedule. Camtek (CAMT) reported Q2 2026 revenue of $133.24M, up 8% YoY, with a strong order book extending into 2027.

$ALABMed

Astera Labs vs. monday.com: Comparing Revenue Trends Between These High-Growth Tech Companies

Astera Labs (ALAB) and monday.com (MNDY) both reported quarterly revenue growth. Astera Labs, which provides semiconductor-based connectivity solutions, saw revenue rise rapidly, surpassing monday.com in Q2 2026. It reported a 39% net income margin and forecasts Q3 revenue of $540M-$560M. monday.com, offering a cloud-native digital work operating system, reported a 6% operating margin and expects Q3 revenue of $368M-$370M, up 16-17% YoY. Both companies have shown consistent growth, with Astera L